Efficacy and Safety of Ravulizumab in IgA Nephropathy: A Phase 2 Randomized Double-Blind Placebo-Controlled Trial

Affiliations

• ¹ Stanford Glomerular Disease Center, Stanford University Medical Center, Stanford, California.
• ² Division of Renal Medicine, Department of Medicine, Emory University, Atlanta, Georgia.
• ³ University Center of Excellence on Nephrological, Rheumatological and Rare Diseases including Nephrology and Dialysis Unit and Center of Immuno-Rheumatology and Rare Diseases, Coordinating Center of the Inter-regional Network for Rare Diseases of Piedmont and Aosta Valley (North-West Italy), San Giovanni Bosco Hub Hospital, ASL Città di Torino, Department of Clinical and Biological Sciences of the University of Turin, Turin, Italy.
• ⁴ Hannover Medical School, Department of Nephrology and Hypertension, Hannover, Germany.
• ⁵ Servicio de Nefrología, UGC Urología-Nefrología, Hospital Virgen del Rocío, Seville, Spain.
• ⁶ Division of Nephrology, Shuang Ho Hospital, Taipei Medical University, Taipei, Taiwan.
• ⁷ Kidney Clinical Research Unit, London Health Sciences Center, East London, Ontario, Canada.
• ⁸ Service de Néphrologie, Hôpital Nord CHU Saint Etienne, Saint Etienne, France.
• ⁹ Department of Internal Medicine, Hallym University Sacred Heart Hospital, Anyang, Korea.
• ¹⁰ AstraZeneca Rare Disease, Alexion, Boston, Massachusetts.
• ¹¹ Department of Cardiovascular Sciences, University of Leicester, Leicester, United Kingdom.